Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Outline of Final Research Achievements |
The central medical therapy of eczema including atopic dermatitis has been both topical steroid and topical immunosuppressant for many years. In this study, we focused on thioredoxin (TRX), which has a crucial role in redox regulation. We demonstrated that topically applied recombinant human TRX (rhTRX) ameliorated a murine irritant contact dermatitis by regulating the epithelial production of pro-Inflammatory cytokines. We made an external agent containing rhTRX, which did not show allergic or irritant reaction in healthy volunteers. We have completed the double-blinded, randomized, placebo-controlled study in 20 patients with atopic dermatitis. Any side effects and harmful phenomenon did not occur in this study. This data are being analyzed.
|